TY - JOUR T1 - Usefulness of GATA-3 as a marker of seminal epithelium in prostate biopsies JO - Actas Urológicas Españolas (English Edition) T2 - AU - Ortiz-Rey,J.A. AU - Chantada-de la Fuente,D. AU - Peteiro-Cancelo,M.Á. AU - Gómez-de María,C. AU - San Miguel-Fraile,M.P. SN - 21735786 M3 - 10.1016/j.acuroe.2017.08.009 DO - 10.1016/j.acuroe.2017.08.009 UR - https://www.elsevier.es/en-revista-actas-urologicas-espanolas-english-392-articulo-usefulness-gata-3-as-marker-seminal-S2173578617301312 AB - ObjectivesThe incidental presence of seminal vesicle epithelium in prostate needle biopsies is generally recognizable through routine microscopy. However, it can sometimes be erroneously interpreted as malignant due to its architectural and cytological characteristics, and immunohistochemistry can be useful for correctly identifying the seminal epithelium. Our objective was to analyze the potential usefulness of GATA-3 as a marker of seminal epithelium. Material and methodsThrough immunohistochemistry with a monoclonal anti-GATA-3 antibody (clone L50-823), we studied seminal vesicle sections from 20 prostatectomy specimens, 12 prostate needle biopsies that contained seminal vesicle tissue and 68 prostate biopsies without seminal vesicle epithelium, 36 of which showed adenocarcinoma. ResultsStaining for GATA-3 was intense in the 20 seminal vesicles of the prostatectomy specimens and in the 12 prostate needle biopsies that contained seminal epithelium. In the 60 biopsies without a seminal vesicle, GATA-3 was positive in the prostate basal cells and even in the secretory cells (57 cases), although with less intensity in 55 of the cases. One of the 36 prostatic adenocarcinomas tested positive for GATA-3. ConclusionsThe intense immunohistochemical expression of GATA-3 in the seminal vesicle epithelium can help identify it in prostate biopsies. This marker is also positive in the basal cells of healthy prostates and, with less intensity, in the secretory cells. Positivity, weak or moderate, is observed on rare occasions in prostatic adenocarcinomas. ER -